Kenjiro Aogi on Muck Rack

Kenjiro Aogi

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Kenjiro

Contact Kenjiro, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Clinical benefit of palbociclib retreatment after abemaciclib exposure in hormone receptor positive, HER2 negative metastatic breast cancer

|
By Muhan Yu, Michiko Yamashita, Mamoru Takada, Daisuke Takabatake, Mina Takahashi, Midori Kondo, Takeshi Nagashima, Hiroshi Fujimoto, Junta Sakakibara, Ryotaro Teranaka, Kenjiro Aogi, Masayuki Otsuka, Mariko Kochi, Maya Uno
| Nature Verified
Abstract Cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) combined with endocrine therapy are standard first-line treatment for HR + /HER2– metastatic breast cancer (MBC). However, disease progression and treatment-limiting adverse events (AEs) remain major challenges, and the clinical benefit of CDK4/6i retreatment after prior exposure is uncertain.
Open in Who Shared Issue with article?
See all 1 licensed articles (2 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified